866-997-4948(US-Canada Toll Free)

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 229 Pages

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2017, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 14, 5, 41 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 11 and 3 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Human Papillomavirus (HPV) Associated Cancer - Overview 9
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 29
Abion Inc 29
Admedus Ltd 29
Advaxis Inc 30
Antigen Express Inc 30
Atara Biotherapeutics Inc 31
BioNTech AG 31
Cancer Research Technology Ltd 32
Cell Medica Ltd 32
Etubics Corp 33
EyeGene Inc 33
Formune SL 34
Genexine Inc 34
Hookipa Biotech AG 35
iBio Inc 35
Immunovaccine Inc 36
Inovio Pharmaceuticals Inc 36
ISA Pharmaceuticals BV 37
Johnson & Johnson 37
Juno Therapeutics Inc 38
Karyopharm Therapeutics Inc 38
Kite Pharma Inc 39
Lion Biotechnologies Inc 39
MedImmune LLC 40
Millennium Pharmaceuticals Inc 40
NeoImmuneTech Inc 41
Onconova Therapeutics Inc 41
Oryx GmbH & Co KG 42
PDS Biotechnology Corp 42
Peregrine Pharmaceuticals Inc 43
Profectus BioSciences Inc 43
Rottapharm Biotech Srl 44
Selecta Biosciences Inc 44
Shantha Biotechnics Ltd 45
Shuttle Pharmaceuticals LLC 45
Sirnaomics Inc 46
Solon Eiendom ASA 46
Theravectys SA 47
THEVAX Genetics Vaccine USA Inc 47
Tomegavax Inc 48
Transgene SA 48
UbiVac LLC 49
Vaccibody AS 49
Vault Pharma Inc 50
Virometix AG 50
VLPbio 51
Human Papillomavirus (HPV) Associated Cancer - Drug Profiles 52
ABI-1968 - Drug Profile 52
ABN-301 - Drug Profile 53
AEH-10p - Drug Profile 54
alisertib - Drug Profile 55
Antibodies to Inhibit E6 for HPV Associated Cancer - Drug Profile 61
Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile 62
ATA-368 - Drug Profile 63
AVA-1001 - Drug Profile 64
axalimogene filolisbac - Drug Profile 65
bavituximab - Drug Profile 83
BVAC-C - Drug Profile 101
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 102
Cellular Immunotherapy for HPV Associated Cervical Cancer - Drug Profile 103
Cellular Immunotherapy to Target HPV E6 and E7 Protein for Oncology - Drug Profile 104
Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 105
Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 107
CerviVax - Drug Profile 109
CMD-004 - Drug Profile 110
CUE-101 - Drug Profile 111
CUE-201 - Drug Profile 112
DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 113
DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 114
DPV-001 - Drug Profile 115
DPV-003 - Drug Profile 117
DPXE-7 - Drug Profile 118
EDA-HPVE7 - Drug Profile 120
EG-HPV - Drug Profile 121
Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 122
ETBX-041 - Drug Profile 123
Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile 124
Gene Therapy to Inhibit E6 and E7 for HPV Associated Cervical Cancer - Drug Profile 125
GX-188E - Drug Profile 126
HB-201 - Drug Profile 128
HPViNT - Drug Profile 129
human papillomavirus (7-valent) vaccine - Drug Profile 130
human papillomavirus [Serotype 16] vaccine - Drug Profile 131
human papillomavirus [serotypes 16] vaccine - Drug Profile 132
human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine biosimilar - Drug Profile 133
human papillomavirus vaccine - Drug Profile 134
human papillomavirus vaccine - Drug Profile 136
human papillomavirus vaccine - Drug Profile 137
INO-3106 - Drug Profile 138
INO-3112 - Drug Profile 139
ISA-101 - Drug Profile 142
ISA-201 - Drug Profile 146
KITE-439 - Drug Profile 147
LN-145 - Drug Profile 149
Monoclonal Antibody Conjugate to Target CD40 for HPV Associated Cervical, Head And Neck Cancer - Drug Profile 151
Monoclonal Antibody to Inhibit E6 for Human Papillomavirus (HPV) Associated Cancer - Drug Profile 152
Monoclonal Antibody to Target E6 and E7 Proteins for Oncology - Drug Profile 153
NIT-02 - Drug Profile 154
NP-001 - Drug Profile 155
NSC-721689 - Drug Profile 156
Oncolytic Virus to Target E6/E7 for HPV Associated Head and Neck Cancer - Drug Profile 157
PDS-0101 - Drug Profile 158
PVX-01 - Drug Profile 160
Recombinant Vector Vaccine to Target Human Papillomavirus Protein E7 for HPV Associated Cervical Cancer - Drug Profile 161
rigosertib sodium - Drug Profile 162
sdCMV-002 - Drug Profile 175
SEL-701 - Drug Profile 176
Small Molecules for Solid Tumors and HPV Associated Cancer - Drug Profile 177
Small Molecules to Inhibit E6 for Human Papillomavirus Associated Cancer - Drug Profile 178
SP-259 - Drug Profile 179
STP-900 - Drug Profile 180
Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile 181
Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 182
TA-CIN - Drug Profile 183
TG-4001 - Drug Profile 185
Tricurin - Drug Profile 187
TVGV-1 - Drug Profile 188
TVGV-2 - Drug Profile 189
Vacc-HPV - Drug Profile 190
Vaccine for HIV and HPV Associated Cancer - Drug Profile 191
Vaccine for HPV Associated Cancer - Drug Profile 192
Vaccine for HPV Associated Cancers - Drug Profile 193
Vaccine for HPV Associated Cervical Cancer - Drug Profile 194
Vaccine for HPV Associated Cervical Cancer - Drug Profile 195
Vaccine for HPV Associated Non-Melanoma Skin Cancer - Drug Profile 196
Vaccine for Human Papillomavirus Associated Cervical Cancer - Drug Profile 197
VB-1016 - Drug Profile 198
verdinexor - Drug Profile 201
VGX-3100 - Drug Profile 202
Vicoryx - Drug Profile 205
VMT-2 - Drug Profile 206
VPI-241 - Drug Profile 207
Vvax-001 - Drug Profile 208
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 209
Human Papillomavirus (HPV) Associated Cancer - Discontinued Products 211
Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 212
Featured News & Press Releases 212
Appendix 222
Methodology 222
Coverage 222
Secondary Research 222
Primary Research 222
Expert Panel Validation 222
Contact Us 222
Disclaimer 223

List of Tables
Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abion Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Ltd, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cell Medica Ltd, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corp, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Formune SL, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Hookipa Biotech AG, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Juno Therapeutics Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune LLC, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by NeoImmuneTech Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co KG, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by PDS Biotechnology Corp, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Rottapharm Biotech Srl, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Ltd, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shuttle Pharmaceuticals LLC, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Solon Eiendom ASA, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Tomegavax Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac LLC, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vault Pharma Inc, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H1 2017
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Human Papillomavirus (HPV) Associated Cancer - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *